| Authors: |
Chu JY; Signalling Programme, The Babraham Institute, Cambridge, UK., Tsonou E; Signalling Programme, The Babraham Institute, Cambridge, UK; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Machin PA; Signalling Programme, The Babraham Institute, Cambridge, UK., MacLellan-Gibson K; Imaging Facility, The Babraham Institute, Cambridge, UK., Roberts AG; Signalling Programme, The Babraham Institute, Cambridge, UK., Chetwynd SA; Signalling Programme, The Babraham Institute, Cambridge, UK., McCormack AT; Department of Chemistry, Maynooth University, Maynooth, Ireland., Stephens JC; Department of Chemistry, Maynooth University, Maynooth, Ireland; The Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Ireland., Benetti E; Department of Drug Science and Technology, University of Turin, Turin, Italy., Kinsella GK; School of Food Sciences and Environmental Health, Technological University Dublin, Dublin, Ireland., Baker D; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Hornigold DC; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Welch HCE; Signalling Programme, The Babraham Institute, Cambridge, UK. Electronic address: heidi.welch@babraham.ac.uk. |
